The DOI matches its Crossref record; 86 of the 93 references it cites were found in a registry or an index.
Proautophagic Drugs: A Novel Means to Combat Apoptosis-Resistant Cancers, with a Special Emphasis on Glioblastomas
Abstract
Learning Objectives: After completing this course, the reader will be able to: Describe the pathways involved in the natural resistance of cancer cells to cytotoxic insults including radio-/chemotherapy.Explain autophagic cell death as a potent alternative tumor-suppressing mechanism.Identify the common targets in apoptosis and autophagy resistance pathways and the surrogate markers that could be used in clinical practice for proautophagic therapy.Discuss the rationale for incorporating endoplasmic reticulum stress inhibitors as adjuvant chemotherapies against apoptosis-resistant cancers. Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As the suppression of autophagy to sustain the cytotoxicity of chemotherapeutic drugs is a novel strategy for cancer chemotherapy3435, HDAC10 is an emerging target for the treatment of advanced-stage neuroblastoma32.”
From Histone deacetylase 10 structure and molecular function as a polyamine deacetylase (2017) · cites this paper as [35]
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Self-eating and self-killing: crosstalk between autophagy and apoptosis
Maiuri, M. C., Zalckvar, E., Kimchi, A., & Kroemer, G. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2239 · Cited by 3,638
Induction of autophagy and inhibition of tumorigenesis by beclin 1
Liang, X. H., Jackson, S., Seaman, M., Brown, K., Kempkes, B., Hibshoosh, H., & Levine, B. (1999) · Nature · doi:10.1038/45257 · Cited by 3,347
de Duve, C., & Wattiaux, R. (1966) · Annual Review of Physiology · doi:10.1146/annurev.ph.28.030166.002251 · Cited by 3,033 · cited 1×
“The autophagy story began in 1966 when De Duve and Wattiaux [ 28 ] discovered lysosomes, with the significance that autophagy is a lysosome-mediated degradation of proteins and cellular organelles [27].”
BackgroundAutophagy in Health and Disease: A Double-Edged Sword
Shintani, T., & Klionsky, D. J. (2004) · Science · doi:10.1126/science.1099993 · Cited by 2,559
The role of autophagy in cancer development and response to therapy
Kondo, Y., Kanzawa, T., Sawaya, R. A., & Kondo, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1692 · Cited by 1,673
Aggarwal, B. B. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.003 · Cited by 1,586
Growth factor regulation of autophagy and cell survival in the absence of apoptosis
Lum, J. J., Bauer, D. E., Kong, M., Harris, M. H., Li, C., Lindsten, T., & Thompson, C. B. (2005) · Cell · doi:10.1016/j.cell.2004.11.046 · Cited by 1,487
Autophagy as a cell death and tumor suppressor mechanism
Gözüaçık, D., & Kimchi, A. (2004) · Oncogene · doi:10.1038/sj.onc.1207521 · Cited by 1,396
Cited by
Sorted by citations
Induction of autophagy by spermidine promotes longevity
Eisenberg, T., Knauer, H., Schauer, A., Büttner, S., Ruckenstuhl, C., Carmona-Gutierrez, D., Ring, J., Schroeder, S., Magnes, C., Antonacci, L., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1975 · Cited by 1,680
Azad, M. B., Chen, Y., & Gibson, S. B. (2008) · Antioxidants and Redox Signaling · doi:10.1089/ars.2008.2270 · Cited by 764
Balamuth, N., & Womer, R. B. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70286-4 · Cited by 727
Salazar‐Roa, M., Carracedo, A., Salanueva, Í. J., Hernández‐Tiedra, S., Lorente, M., Egia, A., Vázquez, P., Blázquez, C., Torres, S., Garcia, S., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37948 · Cited by 700
Mechanisms of drug resistance in colon cancer and its therapeutic strategies
Hu, T., Li, Z., Gao, C.-Y., & Cho, C. H. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i30.6876 · Cited by 381
Metadata
- Authors
- Lefranc, F., Facchini, V., & Kiss, R.
- Affiliations
- Université Libre de Bruxelles (BE)
- c Unibioscreen SA, Brussels, Belgium
- b Laboratory of Toxicology, Institute of Pharmacy, Université Libre de Bruxelles, Brussels, Belgium
- Corresponding author
- Lefranc, Florence
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-12-01
- Volume
- 12
- Issue
- 12
- Pages
- 1395-1403
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2099551830
- Cited by
- 237
- References
- 93
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2023: 7 · 2022: 7 · 2021: 7 · 2020: 5 · 2019: 7 · 2018: 11 · 2017: 14 · 2016: 10 · 2015: 13 · 2014: 13 · 2013: 21 · 2012: 19
- FWCI
- 2.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- The Oncologist (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Keywords
- autophagic cell death, apoptosis resistance, glioblastoma, temozolomide, mTOR inhibitors, PI3K/Akt signaling, endoplasmic reticulum stress, combination chemotherapy, caspase-independent cell death
- MeSH terms
- Temozolomide, Antineoplastic Agents, Autophagy, Dacarbazine, Glioblastoma, Humans, Neoplasms, Drug Delivery Systems, Apoptosis, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
